Enhancement of Tetravalent Immune Responses to Highly Conserved Epitopes of a Dengue Peptide Vaccine Conjugated to Polystyrene Nanoparticles

Chan, Yanqi; Jazayeri, Seyed Davoud; Ramanathan, Babu; Poh, Chit Laa

doi:10.3390/vaccines8030417

Cited by 16 publications

(9 citation statements)

References 57 publications

(77 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 59 Moreover, an in silico multi-epitope tetravalent dengue vaccine which has been shown to elicit significant levels of IFN- and neutralizing antibodies has also been developed. 60 …”

Section: Discussionmentioning

confidence: 99%

Multi Epitope-Based Vaccine Design for Protection Against Mycobacterium tuberculosis and SARS-CoV-2 Coinfection

Pitaloka¹,

Izzati²,

Amirah³

et al. 2022

AABC

View full text Add to dashboard Cite

Background A prophylactic and immunotherapeutic vaccine for Mycobacterium tuberculosis (MTB) and SARS-CoV-2 coinfection needs to be developed for a proactive and effective therapeutic approach. Therefore, this study aims to use immunoinformatics to design a multi-epitope vaccine for protection against MTB and SARS-CoV-2 coinfection. Methods The bioinformatic techniques were used to screen and construct potential epitopes from outer membrane protein A Rv0899 of MTB and spike glycoprotein of SARS-CoV-2 for B and T cells. The antigenicity, allergenicity, and several physiochemical properties of the developed multi-epitope vaccination were then evaluated. Additionally, molecular docking and normal mode analysis (NMA) were utilized in evaluating the vaccine’s immunogenicity and complex stability. Results Selected proteins and predicted epitopes suggest that the vaccine prediction can be helpful in the protection against both SARS-CoV-2 and MTB coinfection. Through docking molecular and NMA, the vaccine-TLR4 protein interaction was predicted to be efficient with a high level of IgG, T-helper cells, T-cytotoxic cells, andIFN-γ. Conclusion This epitope-based vaccine is a potentially attractive tool for SARS-CoV-2 and MTB coinfection vaccine development.

show abstract

“… 59 Moreover, an in silico multi-epitope tetravalent dengue vaccine which has been shown to elicit significant levels of IFN- and neutralizing antibodies has also been developed. 60 …”

Section: Discussionmentioning

confidence: 99%

Multi Epitope-Based Vaccine Design for Protection Against Mycobacterium tuberculosis and SARS-CoV-2 Coinfection

Pitaloka¹,

Izzati²,

Amirah³

et al. 2022

AABC

View full text Add to dashboard Cite

show abstract

“…Additionally, conserved serotype-specific motifs were discovered in NS1, NS5, Capsid, PrM, and Envelope proteins. Chan et al ( 2020 ) developed four multi-epitope peptides (P1–P4) against all four DENV serotypes by connecting a universal T-helper epitope (PADRE or TpD) to a highly conserved CD8 T cell epitope and a B cell epitope (B1 or B2). Four nanovaccines (NP1–NP4) were developed using the multi-epitope peptides conjugated to polystyrene nanoparticles (PSNPs).…”

Section: Discussionmentioning

confidence: 99%

Design of Monovalent and Chimeric Tetravalent Dengue Vaccine Using an Immunoinformatics Approach

Dixit¹

2021

Int J Pept Res Ther

View full text Add to dashboard Cite

An immunoinformatics technique was used to predict a monovalent amide immunogen candidate capable of producing therapeutic antibodies as well as a potent immunogen candidate capable of acting as a universal vaccination against all dengue fever virus serotypes. The capsid protein is an attractive goal for anti-DENV due to its position in the dengue existence cycle. The widely accessible immunological data, advances in antigenic peptide prediction using reverse vaccinology, and the introduction of molecular docking in immunoinformatics have directed vaccine manufacturing. The C-proteins of DENV-1-4 serotypes were known as antigens to assist with logical design. Binding epitopes for TC cells, TH cells, and B cells is predicted from structural dengue virus capsid proteins. Each T cell epitope of C-protein integrated with a B cell as a templet was used as a vaccine and produce antibodies in contrast to serotype of the dengue virus. A chimeric tetravalent vaccine was created by combining four vaccines, each representing four dengue serotypes, to serve as a standard vaccine candidate for all four Sero groups. The LKRARNRVS, RGFRKEIGR, KNGAIKVLR, and KAINVLRGF from dengue 1, dengue 2, dengue 3, and dengue 4 epitopes may be essential immunotherapeutic representatives for controlling outbreaks.

show abstract

“…Multi-epitope vaccines offer a viable alternative since they can elicit potent immune responses without causing undesirable allergic reactions and have been already used against a variety of Influenza strains successfully (Rakib et al 2020 ). These vaccines are a group of recombinant products with high specificity, safety, stability and low-cost of production (Chan et al 2020 ). Therefore, any study that could help to improve the quality of these agents is important.…”

Section: Discussionmentioning

confidence: 99%

Computational Design and Analysis of a Multi-epitope Against Influenza A virus

Rostaminia

Aghaei

Farahmand

et al. 2021

Int J Pept Res Ther

View full text Add to dashboard Cite

Influenza A viruses are among the most studied viruses, however no effective prevention against influenza infection has been developed. So, designing an effective vaccine against Influenza A virus is a critical issue in the field of medical biotechnology. For this reason, to combat this disease, we have designed a novel multi-epitope vaccine candidate based on the several conserved and potential linear B-cell and T-cell binding epitopes by using the in silico approach. This vaccine consists of an ER signal conserved sequence, the PADRE conserved epitope and two conserved epitopes of Influenza matrix protein 2. T-cell binding epitopes from Matrix protein 2 were predicted by in silico tools of epitope prediction. The selected epitopes were joined by flexible linkers and physicochemical properties, toxicity, and allergenecity were investigated. The designed vaccine was antigenic, immunogenic, and non-allergenic with suitable physicochemical properties and has higher solubility. The final multi-epitope construct was modeled, confirmed by different programs and the molecular interactions with immune receptors were considered. The molecular docking assay indicated the interactions with immune-stimulatory toll-like receptor 3 (TLR3) and major histocompatibility complex class I (MHCI). The HADDOCK and H DOCK servers were used to make docking analysis, respectively. The docking analysis indicated a strong and stable binding interaction between the vaccine construct with major histocompatibility complex (MHC) class I and toll-like receptor 3. Overall, the findings suggest that the current vaccine may be a promising vaccine to prevent Influenza infection.

show abstract

Enhancement of Tetravalent Immune Responses to Highly Conserved Epitopes of a Dengue Peptide Vaccine Conjugated to Polystyrene Nanoparticles

Cited by 16 publications

References 57 publications

Multi Epitope-Based Vaccine Design for Protection Against Mycobacterium tuberculosis and SARS-CoV-2 Coinfection

Multi Epitope-Based Vaccine Design for Protection Against Mycobacterium tuberculosis and SARS-CoV-2 Coinfection

Design of Monovalent and Chimeric Tetravalent Dengue Vaccine Using an Immunoinformatics Approach

Computational Design and Analysis of a Multi-epitope Against Influenza A virus

Contact Info

Product

Resources

About